X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8808) 8808
Book Review (1806) 1806
Publication (506) 506
Newsletter (184) 184
Book Chapter (87) 87
Book / eBook (21) 21
Conference Proceeding (12) 12
Magazine Article (6) 6
Dissertation (2) 2
Web Resource (2) 2
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7719) 7719
humans (7501) 7501
female (4535) 4535
male (4020) 4020
middle aged (3192) 3192
adult (3155) 3155
aged (2087) 2087
endocrinology & metabolism (1843) 1843
adenoma (1576) 1576
tumors (1459) 1459
adenoma - drug therapy (1375) 1375
abridged index medicus (1369) 1369
oncology (1187) 1187
adenoma - pathology (1185) 1185
pituitary neoplasms - drug therapy (1154) 1154
adenoma - surgery (1137) 1137
cancer (1103) 1103
animals (1092) 1092
surgery (1064) 1064
adenoma - complications (996) 996
medicine & public health (944) 944
treatment outcome (887) 887
adolescent (793) 793
pituitary neoplasms - surgery (739) 739
colorectal cancer (724) 724
diagnosis (719) 719
adenoma - metabolism (707) 707
adenoma - diagnosis (702) 702
adenomas (684) 684
pituitary neoplasms - pathology (658) 658
pituitary neoplasms - complications (655) 655
care and treatment (614) 614
magnetic resonance imaging (610) 610
retrospective studies (608) 608
research (602) 602
risk factors (579) 579
expression (559) 559
gastroenterology & hepatology (538) 538
pituitary adenoma (537) 537
follow-up studies (524) 524
pituitary neoplasms - metabolism (517) 517
acromegaly (513) 513
bromocriptine - therapeutic use (511) 511
therapy (507) 507
acromegaly - drug therapy (490) 490
aged, 80 and over (489) 489
health aspects (486) 486
management (485) 485
medicine, general & internal (482) 482
mice (480) 480
somatostatin - analogs & derivatives (466) 466
diagnosis, differential (454) 454
pituitary-adenomas (453) 453
pituitary (450) 450
octreotide - therapeutic use (447) 447
diabetes (444) 444
immunohistochemistry (439) 439
clinical neurology (433) 433
pregnancy (432) 432
analysis (414) 414
pituitary neoplasms - diagnosis (414) 414
carcinoma (392) 392
adenoma - genetics (388) 388
prognosis (388) 388
time factors (382) 382
young adult (373) 373
prolactin - blood (371) 371
endocrinology (368) 368
child (362) 362
antineoplastic agents - therapeutic use (361) 361
pathology (361) 361
somatostatin - therapeutic use (352) 352
transsphenoidal surgery (351) 351
adenoma - secretion (348) 348
pituitary neoplasms - secretion (343) 343
risk (336) 336
octreotide (324) 324
prevention (321) 321
apoptosis (320) 320
tomography, x-ray computed (320) 320
colonoscopy (319) 319
adenoma, islet cell - drug therapy (318) 318
article (318) 318
mutation (310) 310
bromocriptine (308) 308
adenoma - blood (306) 306
prolactin (304) 304
adenoma - therapy (302) 302
combined modality therapy (300) 300
genetic aspects (299) 299
pituitary gland tumors (296) 296
mortality (294) 294
dopamine agonists - therapeutic use (293) 293
internal medicine (291) 291
follow-up (288) 288
colorectal neoplasms - pathology (283) 283
drug therapy (283) 283
pancreatic neoplasms - drug therapy (281) 281
gene expression (280) 280
growth-hormone (279) 279
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8311) 8311
French (207) 207
German (197) 197
Japanese (98) 98
Spanish (81) 81
Russian (46) 46
Italian (40) 40
Polish (21) 21
Chinese (19) 19
Hungarian (14) 14
Danish (13) 13
Portuguese (11) 11
Dutch (10) 10
Czech (7) 7
Hebrew (3) 3
Korean (3) 3
Norwegian (3) 3
Bulgarian (1) 1
Croatian (1) 1
Finnish (1) 1
Romanian (1) 1
Slovak (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2013, Volume 31, Issue 34, pp. 4297 - 4305
Journal Article
Urologiia (Moscow, Russia : 1999), ISSN 1728-2985, 03/2018, Issue 1, pp. 101 - 105
Journal Article
by Liu, Y T and Zhang, Y and Wang, Y and Wu, Z B
Zhonghua yi xue za zhi, ISSN 0376-2491, 06/2019, Volume 99, Issue 22, p. 1703
To study the role of dopamine receptor subtype DRD2 and DRD5 in the treatment of pituitary adenoma, and toprovide a novel strategy for the drug-resistant... 
Pituitary Neoplasms | Prolactinoma | Receptors, Dopamine | Receptors, Dopamine D5 | Humans | Receptors, Dopamine D2 | Adenoma | Ergolines
Journal Article
Chinese Journal of New Drugs, ISSN 1003-3734, 03/2015, Volume 24, Issue 6, pp. 649 - 675
Journal Article
Journal Article
Science Signaling, ISSN 1945-0877, 10/2015, Volume 8, Issue 397, pp. ra98 - ra98
Yes-associated protein 1 (YAP1) is a transcriptional coactivator in the Hippo signaling pathway. Increased YAP1 activity promotes the growth of tumors,... 
PHOTODYNAMIC THERAPY | PATHWAY | COLORECTAL-CANCER | BIOCHEMISTRY & MOLECULAR BIOLOGY | HIPPO | GROWTH | MACULAR DEGENERATION | CELL-PROLIFERATION | CHOROIDAL NEOVASCULARIZATION | TEAD/TEF FAMILY | TUMORIGENESIS | CELL BIOLOGY | Transcription, Genetic - drug effects | Phosphorylation | Adenocarcinoma - pathology | Molecular Weight | Apoptosis - drug effects | Colonic Neoplasms - drug therapy | Humans | Neoplasm Proteins - physiology | Colonic Neoplasms - chemically induced | Neoplasm Proteins - antagonists & inhibitors | Phosphoproteins - antagonists & inhibitors | Adenomatous Polyposis Coli - pathology | Autophagy - drug effects | Genes, APC | Neoplasm Proteins - drug effects | Proteasome Endopeptidase Complex - drug effects | Adaptor Proteins, Signal Transducing - antagonists & inhibitors | Adenoma - drug therapy | HEK293 Cells | Antineoplastic Agents - pharmacology | Phosphoproteins - physiology | Adenomatous Polyposis Coli - genetics | Mice, Inbred C57BL | Transcription Factors - antagonists & inhibitors | Porphyrins - pharmacology | Adenocarcinoma - drug therapy | Cell Division - drug effects | Mice, Knockout | Xenograft Model Antitumor Assays | Adaptor Proteins, Signal Transducing - physiology | Animals | Adenomatous Polyposis Coli - drug therapy | Colonic Neoplasms - pathology | Adenoma - pathology | Cell Line, Tumor | Mice | Protein Processing, Post-Translational | STAT3 Transcription Factor - antagonists & inhibitors | Protein Multimerization - drug effects | Index Medicus
Journal Article
Endocrine-related Cancer, ISSN 1351-0088, 2015, Volume 22, Issue 6, pp. 877 - 887
Effective adverse event (AE) management is critical to maintaining patients on anticancer therapies. The DECISION trial was a multicenter, randomized,... 
Adverse events | Targeted therapy | Tyrosine kinase inhibitor | Sorafenib | Differentiated thyroid cancer | targeted therapy | sorafenib | EFFICACY | GUIDELINES | TIME | adverse events | differentiated thyroid cancer | DECREASES | TRIAL | ONCOLOGY | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | tyrosine kinase inhibitor | RENAL-CELL | EXPOSURE | Adenoma, Oxyphilic - enzymology | Dyspnea - chemically induced | Thyroid Neoplasms - enzymology | Prevalence | Adenocarcinoma, Follicular - radiotherapy | Humans | Middle Aged | Drug Resistance, Neoplasm | Hypertension - drug therapy | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Protein Kinase Inhibitors - adverse effects | Weight Loss - drug effects | Incidence | Neoplasms, Second Primary - chemically induced | Adenocarcinoma, Follicular - drug therapy | Adenoma, Oxyphilic - drug therapy | Hypocalcemia - epidemiology | Niacinamide - adverse effects | Carcinoma, Papillary - drug therapy | Niacinamide - therapeutic use | Thyroid Neoplasms - radiotherapy | Adenocarcinoma, Follicular - enzymology | Neoplasms, Second Primary - epidemiology | Niacinamide - analogs & derivatives | Diarrhea - epidemiology | Diarrhea - chemically induced | Iodine Radioisotopes - therapeutic use | Hypocalcemia - chemically induced | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Female | Carcinoma, Papillary - enzymology | Hypertension - epidemiology | Adenoma, Oxyphilic - radiotherapy | Drug Eruptions - etiology | Phenylurea Compounds - therapeutic use | Dyspnea - epidemiology | Disease-Free Survival | Carcinoma, Papillary - radiotherapy | Fatigue - epidemiology | Thyroid Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Aged | Diarrhea - drug therapy | Drug Eruptions - epidemiology | Radiopharmaceuticals - therapeutic use | Index Medicus | Research
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 12/2011, Volume 121, Issue 12, pp. 4712 - 4721
Cushing disease is a condition in which the pituitary gland releases excessive adrenocorticotropic hormone (ACTH) as a result of an adenoma arising from the... 
NUCLEAR-LOCALIZATION | MEDICINE, RESEARCH & EXPERIMENTAL | DEPENDENT CUSHINGS-SYNDROME | GEFITINIB INDUCES APOPTOSIS | CYCLE INHIBITOR P27(KIP1) | EPIDERMAL-GROWTH-FACTOR | PROOPIOMELANOCORTIN GENE | CORTICOTROPH TUMORS | T-BOX FACTOR | FACTOR RECEPTOR | PROGNOSTIC VALUE | ACTH-Secreting Pituitary Adenoma - drug therapy | Neoplasm Transplantation | Humans | Cell Line, Tumor - drug effects | Molecular Targeted Therapy | Pituitary ACTH Hypersecretion - drug therapy | ACTH-Secreting Pituitary Adenoma - complications | Adenoma - enzymology | Adenoma - complications | Dog Diseases - drug therapy | Dog Diseases - etiology | Secretory Rate - drug effects | Adenoma - drug therapy | Corticosterone - blood | Gene Expression Regulation, Neoplastic - drug effects | Pro-Opiomelanocortin - genetics | Adenoma - veterinary | Promoter Regions, Genetic | Pituitary ACTH Hypersecretion - etiology | ACTH-Secreting Pituitary Adenoma - veterinary | Cell Line, Tumor - enzymology | Tumor Burden | Adrenocorticotropic Hormone - secretion | Pituitary ACTH Hypersecretion - blood | Adenoma - blood | Dog Diseases - blood | ACTH-Secreting Pituitary Adenoma - blood | Animals | Mice, Nude | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Dogs | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Protein Kinase Inhibitors - pharmacology | ACTH-Secreting Pituitary Adenoma - enzymology | Pituitary ACTH Hypersecretion - veterinary | Quinazolines - pharmacology | Drug Screening Assays, Antitumor | Care and treatment | Pituitary gland tumors | ACTH | Drug targeting | Adenoma | Diagnosis | Research | Properties | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 475 - 483
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 61, Issue 5, pp. 1088 - 1096
Background & Aims Although the growth suppressing Hippo pathway has been implicated in hepatocellular carcinoma (HCC) pathogenesis, it is unknown at which... 
Gastroenterology and Hepatology | Preneoplastic stages | HCC | Verteporfin | TCPOBOP | Hippo pathway | YES-ASSOCIATED PROTEIN | RAT | ORGAN SIZE CONTROL | REGENERATION | CELL-PROLIFERATION | LESIONS | CARCINOGENESIS | PATHWAY | HEPATOCELLULAR-CARCINOMA DEVELOPMENT | GASTROENTEROLOGY & HEPATOLOGY | TUMORIGENESIS | Adenoma, Liver Cell - drug therapy | Precancerous Conditions - etiology | Adenoma, Liver Cell - etiology | Humans | Middle Aged | Rats, Inbred F344 | Male | MicroRNAs - metabolism | Precancerous Conditions - metabolism | Phosphoproteins - metabolism | Liver Neoplasms - etiology | Precancerous Conditions - drug therapy | Young Adult | Liver Neoplasms, Experimental - metabolism | Carcinoma, Hepatocellular - drug therapy | Apoptosis Regulatory Proteins - genetics | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Hepatocellular - etiology | Protein-Serine-Threonine Kinases - metabolism | Gene Expression | Signal Transduction | Adenoma, Liver Cell - metabolism | Liver Neoplasms - drug therapy | Rats | Porphyrins - pharmacology | Liver Neoplasms, Experimental - etiology | Apoptosis Regulatory Proteins - metabolism | Animals | Liver Neoplasms, Experimental - drug therapy | Apoptosis Regulatory Proteins - antagonists & inhibitors | Liver Neoplasms - metabolism | Cell Line, Tumor | Aged | Cell Proliferation - drug effects | Mice | MicroRNAs - genetics | Adaptor Proteins, Signal Transducing - metabolism | Carcinoma, Hepatocellular - metabolism | Liver cancer | Health aspects | Index Medicus
Journal Article
European Journal of Endocrinology, ISSN 0804-4643, 2014, Volume 170, Issue 4, pp. 575 - 582
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 12, pp. 1085 - 1095
Among patients with endoscopically resected early gastric cancers who were infected with Helicobacter pylori , the incidence of metachronous gastric cancer was... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | CARCINOGENESIS | ENDOSCOPIC RESECTION | RISK | CLASSIFICATION | ERADICATION | INFECTION | RANDOMIZED CONTROLLED-TRIAL | CARCINOMA | Adenoma - surgery | Prospective Studies | Follow-Up Studies | Rabeprazole - therapeutic use | Humans | Middle Aged | Helicobacter Infections - complications | Male | Neoplasm Recurrence, Local - etiology | Incidence | Anti-Bacterial Agents - therapeutic use | Helicobacter pylori | Helicobacter Infections - drug therapy | Adult | Female | Gastritis, Atrophic - etiology | Stomach Neoplasms - epidemiology | Drug Therapy, Combination | Stomach Neoplasms - etiology | Stomach - pathology | Double-Blind Method | Neoplasm Recurrence, Local - prevention & control | Kaplan-Meier Estimate | Clarithromycin - therapeutic use | Gastroscopy | Proton Pump Inhibitors - therapeutic use | Stomach Neoplasms - prevention & control | Amoxicillin - therapeutic use | Intention to Treat Analysis | Aged | Neoplasm Recurrence, Local - epidemiology | Stomach Neoplasms - surgery | Prevention | Treatment outcome | Usage | Patient outcomes | Analysis | Proton pump inhibitors | Stomach cancer | Bacterial infections | Enrollments | Gastric mucosa | Mucosa | Systematic review | Infections | Adenoma | Metastasis | Patients | Meta-analysis | Atrophy | Motivation | Antibiotics | Biopsy | Classification | Endoscopy | Gastric cancer | Long-term effects | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
European Journal of Endocrinology, ISSN 0804-4643, 06/2017, Volume 176, Issue 6, pp. 769 - 777
Objectives: Only few retrospective studies have reported an efficacy rate of temozolomide (TMZ) in pituitary tumors (PT), all around 50%. However, the... 
RESISTANT | DIAGNOSIS | MANAGEMENT | THERAPY | PROTEIN | ENDOCRINOLOGY & METABOLISM | MGMT PROMOTER METHYLATION | EXPERIENCE | PRIMARY BRAIN | ADENOMAS | ACTH-Secreting Pituitary Adenoma - drug therapy | ACTH-Secreting Pituitary Adenoma - prevention & control | Follow-Up Studies | Dacarbazine - therapeutic use | Tumor Burden - radiation effects | Humans | Drug Resistance, Neoplasm | Male | Practice Patterns, Physicians | Chemoradiotherapy | Prolactinoma - prevention & control | Prolactinoma - radiotherapy | Neoplasm Recurrence, Local - pathology | Neoplasm Grading | Dacarbazine - analogs & derivatives | Adult | Female | Pituitary Neoplasms - radiotherapy | Retrospective Studies | Carcinoma - pathology | France | Prolactinoma - drug therapy | Pituitary Neoplasms - prevention & control | Prolactinoma - pathology | ACTH-Secreting Pituitary Adenoma - radiotherapy | Carcinoma - drug therapy | Neoplasm Recurrence, Local - prevention & control | Neoplasm Invasiveness | Carcinoma - prevention & control | Pituitary Neoplasms - pathology | Carcinoma - radiotherapy | Antineoplastic Agents, Alkylating - therapeutic use | Pituitary Neoplasms - drug therapy | Tumor Burden - drug effects | Survival Analysis | Neoplasm Recurrence, Local - epidemiology | Temozolomide | ACTH-Secreting Pituitary Adenoma - pathology | Cohort Studies | Carcinoma | Brain tumors | Pituitary | Standardization | Radiation therapy | Survival | Patients | Tumors | Index Medicus
Journal Article